Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026)
Bioventus' (BVS) quarterly Income from Non-Controlling Interests came in at $3.0 million in Q2 2026, up 40.89% on a YoY basis from $2.1 million in Q2 2025, and up 258.22% quarter-over-quarter from $833000.0 in Q1 2026.
Analysis
Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Bioventus (BVS) has reported Income from Non-Controlling Interests for 7 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Non-Controlling Interests rose 40.89% year-over-year to $3.0 million; the trailing twelve-month figure through Jun 2026 stood at $7.1 million (up 1034.08% YoY), and the FY2025 full-year result was $4.5 million, up 141.58% from the prior year.
- Income from Non-Controlling Interests grew to $3.0 million in Q2 2026 per BVS's latest filing, from $833000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $3.0 million in Q2 2026 and bottomed at -$28.2 million in Q4 2022.
- Historically, Income from Non-Controlling Interests has averaged -$3.8 million across 5 years, with a median of -$906000.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests slumped 2069.38% in 2022, then jumped 1964.06% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$8.2 million in 2022, then soared by 81.07% to -$1.6 million in 2023, then jumped by 91.79% to -$128000.0 in 2024, then surged by 1964.06% to $2.4 million in 2025, then increased by 25.06% to $3.0 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $3.0 million, $833000.0, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 6.60 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 9.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -2.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -500,000.00 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | - |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 900,000.00 |
| 10 | Bioventus | 923.70 Mn | 894.24 Mn | 105.67 Mn | 2.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 2.98 Mn |
| Mar 28, 2026 | 833,000.00 |
| Dec 31, 2025 | 2.39 Mn |
| Sep 27, 2025 | 851,000.00 |
| Jun 28, 2025 | 2.12 Mn |
| Mar 29, 2025 | -685,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Sep 28, 2024 | -683,000.00 |
| Jun 29, 2024 | -8.62 Mn |
| Mar 30, 2024 | -1.49 Mn |
| Dec 31, 2023 | -1.56 Mn |
| Sep 30, 2023 | -1.49 Mn |
| Jul 1, 2023 | -1.05 Mn |
| Apr 1, 2023 | -20.36 Mn |
| Dec 31, 2022 | -8.24 Mn |
| Oct 1, 2022 | -28.20 Mn |
| Jul 2, 2022 | -762,000.00 |
| Apr 2, 2022 | -3.53 Mn |
| Dec 31, 2021 | -1.53 Mn |
| Oct 2, 2021 | -1.30 Mn |